CHSJ

Curr Health Sci J, vol. 49, no. 2, 2023

Investigating the Neuroprotective and Neuroregenerative Effect of Trazodone Regarding Behavioral Recovery in a BL6C57 Mice Stroke Model

[Original Paper]

IKS Boboc(1,2,3), AC Chirea(2), V Gheorman(4), A Gresita(5), TA Balseanu(2), B Catalin(2), D Calina(6)


(1)U.M.F. Doctoral School Craiova, University of Medicine and Pharmacy of Craiova, Romania,
(2)Experimental Research Centre for Normal and Pathological Aging, University of Medicine and Pharmacy of Craiova, Romania,
(3)Department of Pharmacology, Faculty of Pharmacy, University of Medicine and Pharmacy of Craiova, Romania,
(4)Department of Psychiatry, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, Romania,
(5)College of Osteopathic Medicine, New York Institute of Technology, Old Westbury, NY
(1)
(1)
(5)
(6)
(8), USA,
(6)Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, Romania


Abstract:

Stroke is a major cause of death and disability worldwide. Between 1990 and 2010, its global burden increased notably with reference to the absolute number of incident events, number of deaths, and disability-adjusted life-years lost. Trazodone is a triazolopyridine derivative that was approved for more than 40 years as monotherapy or in combination with other antidepressant drugs for the treatment of major depressive disorder in adult patients. The aim was investigated if trazodone can improve behavioural outcome after stroke in a mice model of middle cerebral artery occlusion (MCAo) due to the potential neuroprotective and neurodegenerative effects by using three behavioural tests: adhesive tape test, beam test and hole board test. Trazodone administration show modest improvements regarding the motor-sensorial function after stroke especially in the acute post-stroke phase in aged and young animals. The antidepressant effect of the drug was observed in the post-stroke period in aged animals and to a lesser extent in young animals. Future research is needed to evaluate the effects of trazodone at the cellular level to be sure that it has no benefit in stroke patients who do not suffer from depression.


Keywords: Stroke, behavioural test, trazodone, drug repurposing.



Corresponding: Bogdan Catalin, Experimental Research Centre for Normal and Pathological Aging, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania, e-mail: bogdan.catalin@umfcv.ro


DOI 10.12865/CHSJ.49.02.10 - Download PDF
current issue cover Download cover
Download contents

Journal archive